CeleCor’s Phase 3 Trial of Disaggpro™ Shows Positive Results

CeleCor Therapeutics announced that its multinational Phase 3 CeleBrate trial of the investigational heart-attack drug Disaggpro™ (zalunfiban) has met its primary efficacy and primary safety outcomes.

Full study results will be presented on November 10 during the late-breaking sessions at the American Heart Association Scientific Sessions in New Orleans.

The Urgent Need for Pre-Hospital Treatment

• At least 50% of heart-attack deaths occur before patients reach the hospital.
• In-hospital treatments for heart attacks have advanced significantly.
• Yet, in the U.S., aspirin remains the only routinely used antiplatelet therapy before hospital arrival.

Disaggpro was developed to fill this critical gap, enabling treatment in pre-hospital settings for patients experiencing ST-segment elevation myocardial infarction (STEMI)—the most severe type of heart attack.

Why It Matters

• STEMI heart attacks account for ~40% of heart-attack cases.
• In STEMI, a blood clot almost always blocks blood flow to part of the heart.
• The key to survival is restoring blood flow as quickly as possible to prevent death or irreversible heart damage.

About Disaggpro™ (Zalunfiban)

• Drug class: Next-generation investigational GPIIb/IIIa inhibitor.
• Formulation: Subcutaneous injection via auto-injector.
• Volume: Full therapeutic dose in <1 mL (less than ¼ teaspoon).
• Onset: Maximal effect within 15 minutes.
• Pharmacokinetics: Half-life of ~1 hour.

This design makes Disaggpro suitable for rapid administration outside the hospital.

The CeleBrate Study

• Design: Pivotal Phase 3, prospective, double-blinded, randomized, placebo-controlled.
• Intervention: Single subcutaneous injection of Disaggpro in STEMI patients before hospital arrival.
• Enrollment: 2,467 patients.
• Sites: 45 locations across the United States, Canada, Mexico, and Europe.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!